17 results on '"Yan, Xiao-Yan"'
Search Results
2. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
- Author
-
Ma, Ya-Fang, Lu, Ying, Wu, Qian, Lou, Yin-Jun, Yang, Min, Xu, Jie-Yu, Sun, Cai-Hong, Mao, Li-Ping, Xu, Gai-Xiang, Li, Li, Huang, Jian, Wang, Huai-Yu, Lou, Li-Jiang, Meng, Hai-Tao, Qian, Jie-Jing, Yu, Wen-Juan, Wei, Ju-Ying, Li, Zhen-Yu, Zhu, Xue-Lu, Yan, Xiao-Yan, Chen, Su-Ning, Jin, Jie, and Zhu, Hong-Hu
- Published
- 2022
- Full Text
- View/download PDF
3. Accuracy of different registration areas using active and passive dynamic navigation systems in dental implant surgery: An in vitro study
- Author
-
Wu, Bin‐Zhang, primary, Ma, Fei‐Fei, additional, Yan, Xiao‐Yan, additional, and Sun, Feng, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Intermittent theta-burst stimulation combined with physical therapy as an optimal rehabilitation in Parkinson's disease: study protocol for a randomised, double-blind, controlled trial.
- Author
-
Jin, Zhao-hui, Wang, Yi-xuan, Meng, De-tao, Qin, Yi, Duan, Yi-nan, Fang, Jin-ping, Wang, Rui-dan, Liu, Yan-jun, Liu, Cui, Wang, Ping, Yan, Hong-jiao, Zhen, Yi, An, Xia, Chen, Ke-ke, Yu, Xin, Lyu, Diyang, Yan, Xiao-Yan, and Fang, Bo-yan
- Subjects
PARKINSON'S disease ,DEEP brain stimulation ,TRANSCRANIAL magnetic stimulation ,PHYSICAL therapy ,FUNCTIONAL training ,REHABILITATION ,RESEARCH protocols - Abstract
Background: First-line rehabilitative strategies to improve motor deficits are based on functional training (physical or occupational therapy), which has been demonstrated to facilitate neural reorganisation. Accumulating evidence suggests that non-invasive brain stimulation techniques, such as repetitive TMS (rTMS), may enhance neuroplasticity, thereby facilitating neural reorganisation and recovery from Parkinson's disease. Evidence also shows that intermittent theta-burst stimulation (iTBS) can improve motor function and quality of life in patients by promoting the excitability and neural remodelling of cerebral cortex. We aimed to combine iTBS stimulation with physiotherapy to improve the rehabilitation effect compared to physiotherapy alone in patients with Parkinson's disease. Methods: This randomised, double-blind clinical trial will enrol 50 Parkinson's disease patients aged 45–70 years with Hoehn and Yahr scale scores of 1–3. Patients are randomly assigned to either the iTBS + physiotherapy or sham-iTBS + physiotherapy group. The trial consists of a 2-week double-blind treatment period and a 24-week follow-up period. iTBS and sham-iTBS will be administered twice daily for 10 days based on physiotherapy. The primary outcome will be the third part of Movement Disorders–Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) from the baseline to the first 2 days following completion hospitalised intervention. The secondary outcome will be 39-item Parkinson's Disease Questionnaire (PDQ-39) at 4 weeks, 12 weeks and 24 weeks after intervention. Tertiary outcomes are clinical evaluations and mechanism study outcomes such as NMSS, 6MWD, 10MT, TUG, BBS, MRI, and EEG, the length of time between the drug needs to be adjusted when symptoms fluctuate. Discussion: The aim of this study is to demonstrate that iTBS can promote overall function and quality of life in Parkinson's disease patients using physiotherapy and that this efficacy may be associated with altered neuroplasticity in exercise-related brain regions. The iTBS combined with physiotherapy training model will be evaluated during a 6-month follow-up period. With significant improvement in quality of life and motor function, iTBS combined with physiotherapy can be considered as a first-line rehabilitation option for Parkinson's disease. The potential of iTBS to enhance neuroplasticity in the brain should have a more positive impact in increasing the generality and efficiency of physiotherapy, improving the quality of life and overall functional status of patients with Parkinson's disease. Trial registration: Chinese Clinical Trial Registry ChiCTR2200056581. Registered on 8 February 2022. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Analysis of Chinese Core Literatures on Protective Clothing Research
- Author
-
Yan, Xiao-Yan, primary, Chen, Xiao-Peng, additional, Zhang, Jia-Min, additional, null, Jie Wang, additional, and Huang, Zhao-Qi, additional
- Published
- 2022
- Full Text
- View/download PDF
6. A Cross-sectional Analysis of MEP Urine Content and Asthma Incident in US Children and Adolescents
- Author
-
Cao, Ren Shuang, primary, Huang, Tian Jiao, additional, Zhang, Wei, additional, Yang, Fan, additional, Liu, Xue, additional, and Yan, Xiao Yan, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Mechanism of Learning and Memory Impairment in Rats Exposed to Arsenic and/or Fluoride Based on Microbiome and Metabolome.
- Author
-
ZHANG, Xiao Li, YU, Sheng Nan, QU, Ruo Di, ZHAO, Qiu Yi, PAN, Wei Zhe, CHEN, Xu Shen, ZHANG, Qian, LIU, Yan, LI, Jia, GAO, Yi, LYU, Yi, YAN, Xiao Yan, LI, Ben, REN, Xue Feng, and QIU, Yu Lan
- Subjects
TROPANES ,MEMORY disorders ,FLUORIDES ,SCOPOLAMINE ,ARSENIC ,LIPOIC acid ,ARACHIDONIC acid ,GUT microbiome - Abstract
Arsenic (As) and fluoride (F) are two of the most common elements contaminating groundwater resources. A growing number of studies have found that As and F can cause neurotoxicity in infants and children, leading to cognitive, learning, and memory impairments. However, early biomarkers of learning and memory impairment induced by As and/or F remain unclear. In the present study, the mechanisms by which As and/or F cause learning memory impairment are explored at the multi-omics level (microbiome and metabolome). We stablished an SD rats model exposed to arsenic and/or fluoride from intrauterine to adult period. Arsenic and/fluoride exposed groups showed reduced neurobehavioral performance and lesions in the hippocampal CA1 region. 16S rRNA gene sequencing revealed that As and/or F exposure significantly altered the composition and diversity of the gut microbiome, featuring the Lachnospiraceae_NK4A136_group, Ruminococcus_1, Prevotellaceae_NK3B31_group, [Eubacterium]_ xylanophilum_group. Metabolome analysis showed that As and/or F-induced learning and memory impairment may be related to tryptophan, lipoic acid, glutamate, gamma-aminobutyric acidergic (GABAergic) synapse, and arachidonic acid (AA) metabolism. The gut microbiota, metabolites, and learning memory indicators were significantly correlated. Learning memory impairment triggered by As and/or F exposure may be mediated by different gut microbes and their associated metabolites. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Additional file 1 of Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
- Author
-
Ma, Ya-Fang, Lu, Ying, Wu, Qian, Lou, Yin-Jun, Yang, Min, Xu, Jie-Yu, Sun, Cai-Hong, Mao, Li-Ping, Xu, Gai-Xiang, Li, Li, Huang, Jian, Wang, Huai-Yu, Lou, Li-Jiang, Meng, Hai-Tao, Qian, Jie-Jing, Yu, Wen-Juan, Wei, Ju-Ying, Li, Zhen-Yu, Zhu, Xue-Lu, Yan, Xiao-Yan, Chen, Su-Ning, Jin, Jie, and Zhu, Hong-Hu
- Abstract
Additional file 1. Figure S1. The treatment schema. The consolidation therapy included RIF (60 mg/kg daily in an oral divided dose) in a 4-week-on and 4-week-off regimen for 4 cycles and ATRA (25 mg/m2 daily in an oral divided dose) in a 2-week-on and 2-week-off regimen for 7 cycles. Of note, treatment cycles were counted according to the cycles of ATRA. Figure S2. Flow chart of participants enrollment, treatment and follow-up. 54 patients were enrolled in the clinical trial and an intention-to-treat analysis were performed. Seven patients had major protocol violation. Four of them suffered cerebral hemorrhage in induction therapy, so their physicians advised two cycles of chemotherapy for consolidation therapy and continued with RIF plus ATRA for 7 cycles. One of them changed protocol for a grade 3 hematochezia. One patient returned to his hometown hospital and changed his treatment plan. The last one did not give a specific reason for the change in treatment. Another seven patients were in consolidation process. Two patients were lost to follow-up and one of them had not completed the trial. Thus 39 patients were included in the per-protocol analysis. Figure S3. PML-RARA tested at 3, 5 and 7 months from the beginning of the induction therapy in ITT analysis.Table S1. Characteristics of the Patients. Table S2. Clinical characteristics and treatment of five patients with cerebral hemorrhage. Table S3. Treatment and outcomes of two relapsed patients. Patient No.1 had cerebral hemorrhage at the time of diagnosis. She had a molecular relapse at 11 months after remission and a central nervous system relapse at 13 months. Patient No.2 had a hematologic relapse at 13 months and achieved remission again after RIF plus ATRA reinduction and alive until last follow-up.
- Published
- 2022
- Full Text
- View/download PDF
9. Stabilized cathode/sulfide solid electrolyte interface via Li2ZrO3 coating for all-solid-state batteries.
- Author
-
Zhao, Chen, Liu, Zi-Qiang, Weng, Wei, Wu, Ming, Yan, Xiao-Yan, Yang, Jing, Lu, Huan-Ming, and Yao, Xia-Yin
- Abstract
Copyright of Rare Metals is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
10. Vulnerability assessment of return-to-poverty under poverty elimination in China: A new integrated regional and individual perspective
- Author
-
YAN, Xiao-yan, primary, QI, Xin-hua, primary, PAN, Ying, primary, and LI, Ya-tong, primary
- Published
- 2022
- Full Text
- View/download PDF
11. Mechanism of subchronic vinyl chloride exposure combined with a high‐fat diet on hepatic steatosis
- Author
-
Jia, Jin, primary, Chen, Shi‐qi, additional, Pan, Wei‐zhe, additional, Yu, Sheng‐nan, additional, Zhao, Xiao‐tian, additional, Hao, Yan, additional, Shen, Yong‐mei, additional, Cheng, Ying, additional, Wei, Cai‐ling, additional, Tian, Feng‐jie, additional, Yan, Xiao‐yan, additional, and Qiu, Yu‐lan, additional
- Published
- 2021
- Full Text
- View/download PDF
12. An interfacial self-assembly strategy to fabricate graphitic hollow porous carbon spheres for supercapacitor electrodes
- Author
-
Zhang, Xiao-hua, primary, Gan, Xin-yu, additional, Liu, Bao-sheng, additional, Yan, Xiao-yan, additional, and Zhao, Xin-xin, additional
- Published
- 2021
- Full Text
- View/download PDF
13. GPR56, an Adhesion GPCR with Multiple Roles in Human Diseases, Current Status and Future Perspective.
- Author
-
Fan Y, Yan XY, and Guan W
- Abstract
Human G protein-coupled receptor 56 (GPR56) belongs to a member of the adhesion G-protein coupled receptor (aGPCR) family and widely exists in the central nervous system and various types of tumor tissues. Recent studies have shown that abnormal expression or dysfunction of GPR56 is closely associated with many physiological and pathological processes, including brain development, neuropsychiatric disorders, cardiovascular diseases and cancer progression. In addition, GPR56 has been proven to enhance the susceptibility of some antipsychotics and anticarcinogens in response to the treatment of neuropsychological diseases and cancer. Although there have been some reports about the functions of GPR56, the underlying mechanisms implicated in these diseases have not been clarified thoroughly, especially in depression and epilepsy. Therefore, in this review, we described the molecular structure and signal transduction pathway of GPR56 and carried out a comprehensive summary of GPR56's function in the development of psychiatric disorders and cancer. Our review showed that GPR56 deficiency led to depressive-like behaviors and an increase in resistance to antipsychotic treatment. In contrast, the upregulation of GPR56 contributed to tumor cell proliferation and metastasis in malignant diseases such as glioblastoma, colorectal cancer, and ovarian cancer. Moreover, we elucidated specific signaling pathways downstream of GPR56 related to the pathogenesis of these diseases. In summary, our review provides compelling arguments for an attractive therapeutic target of GPR56 in improving the therapeutic efficiency for patients suffering from psychiatric disorders and cancer., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
14. Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial.
- Author
-
Zou TH, Gao QY, Liu S, Li YQ, Meng XJ, Zhang GX, Tian ZB, Zou XP, He S, Hou XH, Lin R, Li JN, Zhou ZY, Li Y, Wang MC, Wang BM, Tian A, Chen SJ, Cao Q, Li LP, Wang ZR, Shen XZ, Liu BR, Yan XY, Chen YX, and Fang JY
- Subjects
- Humans, Metaplasia, Folic Acid therapeutic use, Gastric Mucosa pathology, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Gastritis, Atrophic drug therapy, Gastritis, Atrophic pathology, Helicobacter Infections complications, Helicobacter Infections drug therapy, Precancerous Conditions drug therapy, Precancerous Conditions pathology, Helicobacter pylori, Drugs, Chinese Herbal
- Abstract
Objective: To investigate the clinical potential and safety of Moluodan to reverse gastric precancerous lesions., Methods: Patients aged 18-70 years diagnosed with moderate-to-severe atrophy and/or moderate-to-severe intestinal metaplasia, with or without low-grade dysplasia, and negative for Helicobacter pylori were recruited in this randomized, double-blind, parallel-controlled trial. The primary outcome was the improvement of global histological diagnosis at 1-year follow-up endoscopy using the operative link for gastritis assessment, the operative link for gastric intestinal metaplasia assessment, and the disappearance rate of dysplasia., Results: Between November 3, 2017 and January 27, 2021, 166 subjects were randomly assigned to the Moluodan group, 168 to the folic acid group, 84 to the combination group, and 84 to the high-dose Moluodan group. The improvement in global histological diagnosis was achieved in 60 (39.5%) subjects receiving Moluodan, 59 (37.8%) receiving folic acid, 26 (32.1%) receiving the combined drugs, and 36 (47.4%) receiving high-dose Moluodan. Moluodan was non-inferior to folic acid (95% confidence interval: -9.2 to 12.5; P = 0.02). High-dose Moluodan had a trend for better protective efficacy, though there was no statistical significance. The disappearance rate of dysplasia was 82.8% in the Moluodan group, which was superior to folic acid (53.9%; P = 0.006). No drug-related serious adverse events were observed., Conclusions: One pack of Moluodan three times daily for 1 year was safe and effective in reversing gastric precancerous lesions, especially dysplasia. Doubling its dose showed a better efficacy trend., (© 2024 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
15. Mechanism of subchronic vinyl chloride exposure combined with a high-fat diet on hepatic steatosis.
- Author
-
Jia J, Chen SQ, Pan WZ, Yu SN, Zhao XT, Hao Y, Shen YM, Cheng Y, Wei CL, Tian FJ, Yan XY, and Qiu YL
- Subjects
- Animals, Fatty Liver chemically induced, Fatty Liver physiopathology, Male, Mice, Mice, Inbred C57BL, Toxicity Tests, Subchronic, Diet, High-Fat adverse effects, Environmental Pollutants toxicity, Fatty Liver pathology, Vinyl Chloride toxicity
- Abstract
Vinyl chloride (VC) is a common industrial organic chlorine and environmental pollutant. In recent years, the dietary structure of residents especially Chinese has gradually shifted to western dietary patterns. VC aggravates dietary fatty acid-induced hepatic steatosis, but its mechanism is still unclear. And if the risk factors for steatosis persist, more severe diseases such as fibrosis and cirrhosis will occur. Therefore, we studied the effects and mechanisms of VC (160 and 800 mg/m
3 ) and its metabolite (chloroacetaldehyde, 2.25, 4.5, and 9 μM) on hepatic steatosis of high-fat diet (HFD)-fed mice and palmitic acid (PA, 100 μM) treated HepG2 cells. Liver and serum biochemical indicators and pathological staining of the liver showed that the hepatic steatosis of VC combined with HFD groups was more severe than that of single-exposure groups (HFD group, low-dose VC group, and high-dose VC group). Moreover, VC enhanced HFD-induced oxidative stress (OS) and endoplasmic reticulum stress (ERS) and further upregulated the expression of sterol regulatory element-binding protein 1 (SREBP-1) and FAS. Besides, antioxidants and ERS inhibitors reduced the steatosis of HepG2 cells induced by VC metabolites and PA. These results suggest that VC exposure can enhance the degree of hepatic steatosis in HFD-fed mice. VC combined with HFD led to OS and ERS and upregulated the expression of de novo lipogenesis-related proteins, which may be related to the occurrence of hepatic steatosis. And the increased expression of CYP2E1 induced by VC combined with HFD may be the cause of OS., (© 2021 John Wiley & Sons, Ltd.)- Published
- 2022
- Full Text
- View/download PDF
16. Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study.
- Author
-
Zhu HH, Ma YF, Yu K, Ouyang GF, Luo WD, Pei RZ, Xu WQ, Hu HX, Mo SP, Xu XH, Lan JP, Shen JP, Shou LH, Qian SX, Feng WY, Zhao P, Jiang JH, Hu BL, Zhang J, Qian SY, Wu GQ, Wu WP, Qiu L, Li LJ, Lang XH, Chen S, Chen LL, Guo JB, Cao LH, Jiang HF, Xia YM, Le J, Zhao JZ, Huang J, Zhang YF, Lv YL, Hua JS, Hong YW, Zheng CP, Wang JX, Hu BF, Chen XH, Zhang LM, Tao S, Xie BS, Kuang YM, Luo WJ, Su P, Guo J, Wu X, Jiang W, Zhang HQ, Zhang Y, Chen CM, Xu XF, Guo Y, Tu JM, Hu S, Yan XY, Yao C, Lou YJ, and Jin J
- Abstract
Most randomized trials for acute promyelocytic leukemia (APL) have investigated highly selected patients under idealized conditions, and the findings need to be validated in the real world. We conducted a population-based study of all APL patients in Zhejiang Province, China, with a total population of 82 million people, to assess the generalization of all-trans retinoic acid (ATRA) and arsenic as front-line treatment. The outcomes of APL patients were also analyzed. Between January 2015 and December 2019, 1,233 eligible patients were included in the final analysis. The rate of ATRA and arsenic as front-line treatment increased steadily from 66.2% in 2015 to 83.3% in 2019, with no difference among the size of the center (≥5 or <5 patients per year, p = 0.12) or age (≥60 or <60 years, p = 0.35). The early death (ED) rate, defined as death within 30 days after diagnosis, was 8.2%, and the 3-year overall survival (OS) was 87.9% in the whole patient population. Age (≥60 years) and white blood cell count (>10 × 10
9 /L) were independent risk factors for ED and OS in the multivariate analysis. This population-based study showed that ATRA and arsenic as front-line treatment are widely used under real-world conditions and yield a low ED rate and a high survival rate, which mimic the results from clinical trials, thereby supporting the wider application of APL guidelines in the future., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Zhu, Ma, Yu, Ouyang, Luo, Pei, Xu, Hu, Mo, Xu, Lan, Shen, Shou, Qian, Feng, Zhao, Jiang, Hu, Zhang, Qian, Wu, Wu, Qiu, Li, Lang, Chen, Chen, Guo, Cao, Jiang, Xia, Le, Zhao, Huang, Zhang, Lv, Hua, Hong, Zheng, Wang, Hu, Chen, Zhang, Tao, Xie, Kuang, Luo, Su, Guo, Wu, Jiang, Zhang, Zhang, Chen, Xu, Guo, Tu, Hu, Yan, Yao, Lou, Jin and the APL Cooperative Group of Zhejiang Province.)- Published
- 2021
- Full Text
- View/download PDF
17. Efficacy of short-term multidisciplinary intensive rehabilitation in patients with different Parkinson's disease motor subtypes: a prospective pilot study with 3-month follow-up.
- Author
-
Chen KK, Jin ZH, Gao L, Qi L, Zhen QX, Liu C, Wang P, Liu YH, Wang RD, Liu YJ, Fang JP, Su Y, Yan XY, Liu AX, and Fang BY
- Abstract
Parkinson's disease (PD) can be classified into three motor-based subtypes: postural instability/gait difficulty (PIGD), tremor dominant (TD), and indeterminate. The neuropathophysiological mechanisms of the three motor subtypes are different, which may lead to different responses to therapy. Sixty-nine patients with idiopathic Parkinson's disease (Hoehn-Yahr stage ≤ 3) were screened from 436 patients with Parkinsonism recruited through outpatient services and the internet. According to the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) TD/PIGD ratio, the patients were divided into PIGD (TD/PIGD ≤ 0.09; n = 36), TD (TD/PIGD ≥1.15; n = 19), and indeterminate (TD/PIGD = 0.90-1.15; n = 14) groups. All patients received 2 weeks of multidisciplinary intensive rehabilitation treatment (MIRT) during hospitalization, as well as a remote home rehabilitation health education class. Compared with the scores at admission, all patients showed significant improvements in their MDS-UPDRS III score, walking ability, balance, and posture control at discharge. Moreover, the MDS-UPDRS III score improvement was greater in the PIGD group than in the TD group. The follow-up data, collected for 3 months after discharge, showed that overall symptom improvement in each group was maintained for 1-3 months. Furthermore, there were no significant differences in the duration or grade effects of symptom improvement among the three groups. These findings suggest that 2 weeks of MIRT is effective for improving motor performance in all three motor subtypes. Patients in the PIGD group had a better response after hospitalization than those in the TD group. This study was approved by the Institutional Ethics Committee of Beijing Rehabilitation Hospital of Capital Medical University of China (approval No. 2018bkky022) on May 7, 2018 and registered with the Chinese Clinical Trial Registry (registration No. ChiCTR1900020771) on January 19, 2019., Competing Interests: None
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.